title: Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.
authors.affiliation: Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: E
authors.initials: E
authors.lastname: McDuffee
authors.affiliation: Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: G
authors.initials: G
authors.lastname: Aue
authors.affiliation: Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: L
authors.initials: L
authors.lastname: Cook
authors.affiliation: Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: C
authors.initials: C
authors.lastname: Ramos-Delgado
authors.affiliation: Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: R
authors.initials: R
authors.lastname: Shalabi
authors.affiliation: Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: T
authors.initials: T
authors.lastname: Worthy
authors.affiliation: Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: P
authors.initials: P
authors.lastname: Vo
authors.affiliation: Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: R W
authors.initials: RW
authors.lastname: Childs
mesh_terms: D064591:Allografts; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D006086:Graft vs Host Disease / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease; D006801:Humans; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D013256:Steroids / Q000008:administration & dosage*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D013256:Steroids; D000077594:Nivolumab; C582435:pembrolizumab